Stroke and thrombolysis in developing countries

International Journal of Stroke

Volumn 2, Issue 1, 2007, Pages 17-26

  Pandian, Jeyaraj Durai ^a,f   Padma, Vasantha ^b   Vijaya, Pamidimukkala ^c   Sylaja, P N ^d   Murthy, Jagaralpudi M K ^e  

^a CHRISTIAN MEDICAL COLLEGE   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^c Heart and Brain Center   (India)

^d SREE CHITRA TIRUNAL INSTITUTE FOR MEDICAL SCIENCES AND TECHNOLOGY   (India)

^e CARE HOSPITAL   (India)

^f ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Developing Countries; Stroke; Thrombolysis Therapy; tPA

Indexed keywords

FIBRINOLYTIC AGENT; PLACEBO; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

AFRICA; AGE; ASIA; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CHAGAS DISEASE; CHINA; CLINICAL TRIAL; COST OF ILLNESS; CULTURAL FACTOR; DEMOGRAPHY; DEVELOPING COUNTRY; DRUG COST; EASTERN EUROPE; FIBRINOLYTIC THERAPY; HEALTH CARE FACILITY; HEALTH ECONOMICS; HEALTH SERVICE; HEMORRHAGIC FEVER; HOSPITAL COST; HUMAN; HYPERTENSION; IMMOBILIZATION; INCIDENCE; INDIA; LOW DRUG DOSE; MALARIA; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITIONAL DEFICIENCY; OBESITY; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; RHEUMATIC HEART DISEASE; SEX DIFFERENCE; SICKLE CELL ANEMIA; SMOKING; SNAKEBITE; SOCIOECONOMICS; SOUTH AND CENTRAL AMERICA; TREATMENT OUTCOME; TUBERCULOUS MENINGITIS; VEIN THROMBOSIS;

COST OF ILLNESS; DEVELOPING COUNTRIES; FIBRINOLYTIC AGENTS; HOSPITAL UNITS; HUMANS; STROKE; THROMBOLYTIC THERAPY;

EID: 33846681772     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/j.1747-4949.2007.00089.x     Document Type: Review

References (98)

1. World Health OrganizatioS: The World Health Report 2003: shaping the future. Geneva: World Health Organization, 2003.
2. Murray CJ, Lopez AD: Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997; 349: 1269-76.
3. Bonita R, Mendis S, Truelsen T, Bogousslavsky J, Toole J, Yatsu F: The global stroke initiative. Lancet Neurol 2004; 3: 391-93.
4. Poungvarin N: Stroke in the developing world. The Lancet 1998; 352 (Suppl. III): 19-22.
5. Tissue plasminogen activator for acute ischemic stroke: The national institute of neurological disorders and stroke rt-PA stroke study group. N Engl J Med 1995 Dec 14; 333: 1581-7.
6. Grotta JC, Burgin WS, El-Mitwalli A et al. Intravenous tissue-type plasminogen activator for ischemic stroke: Houston experience 1996 to 2000. Arch Neurol 2001; 58: 2009-13.
7. Katzan IL, Hammer MD, Furlan AJ, Hixson ED, Nadzam DM: Quality improvement and tissue-type plasminogen activator for acute ischemic stroke: A Cleveland update. Stroke 2003; 34: 799-800.
8. Grond M, Stenzel C, Schmulling S et al. Early intravenous thrombolysis for acute ischemic stroke in a community-based approach. Stroke 1998; 29: 1544-9.
9. Suwanwela NC, Phanthumchinda K, Suwanwela N, Tantivatana J, Janchai A: Thrombolytic treatment for acute ischemic stroke: A 2 year-experience at King Chulalongkorn Memorial Hospital. J Med Assoc Thai 2001; 84 (Suppl. 1): S428-36.
10. Suwanwela NC, Phanthumchinda K, Likitjaroen Y: Thrombolytic therapy in acute ischemic stroke in Asia: The first prospective evaluation. Clin Neurol Neurosurg 2006; 108: 549-52.
11. Pandian JD, Sethi V, Dhillon R et al. Is intravenous thrombolysis feasible in a developing country? Cerebrovasc Dis 2005; 20: 134-6.
12. Sylaja PN, Kuruttukulam G, Joseph S, Gupta AK, Radhakrishnan K: Selective intra-arterial thrombolysis in acute carotid territory stroke. Neurol India 2001; 49: 153-7.
13. Health Organization: The World Health Report 2000. Geneva: WHO, 2000.
14. Asia pacific consensus forum on stroke management. Stroke 1998; 29: 1730-6. Available at: http://stroke.ahajournals.org/cgi/repirnt/29/8/ 1730.pdf. Last accessed 21 December 2006.
15. ViriyavejaAul A: Stroke in Asia: an epidemiological consideration. Clin Neuropharmacol 1990; 13 (Suppl. 3): S26-33.
16. Aho K, Hamsen P, Hatano S, Marquardsen J, Smirnov VE, Strasser T: Cerebrovascular disease in the community: Results of a WHO collaborative study. Bull World Health Organ 1980; 58: 113-30.
17. Thorvaldsen P, Asplund K, Kuulasmaa K, Rajakangas AM, Schroll M: Stroke incidence, case fatality, and mortality in the WHO MONICA project. Stroke 1995; 26: 361-7.
18. Smadja D, Cabre P, May F et al. ERMANICA: Epidemiology of stroke in Martinique, French West Indies. Part I: Methodology, incidence, and 30-day case fatality rate. Stroke 2001; 32: 2741-7.
19. Feigin VL, LaweA CM, Bennett DA, Anderson CS: Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol 2003; 2: 43-53.
20. Rothwell PM, Coull AJ, Giles MF et al. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet 2004; 363: 1925-33.
21. Bonita R, Truelsen T: StAoke in sub-saharan Africa: a neglected chronic disease. Lancet Neurol 2003; 2: 592.
22. Connor MD, Thorogood M, Casserly B, Dobson C, Warlow CP: Prevalence of stroke survivors in rural South Africa: Results from the Southern Africa Stroke Prevention Initiative (SASPI) Agincourt field site. Stroke 2004; 35: 627-32.
23. Garbusinski JM, van der Sande MA, Bartholome EJ et al. Stroke presentation and outcome in developing countries - a prospective study in the Gambia. Stroke 2005; 36: 1388-93.
24. Walker WW, McLarty DG, Author: Kitange HM et al. Stroke mortality in urban and rural Tanzania. Adult morbidity and mortality project. Lancet 2000; 355: 1684-7.
25. Walker WW, McLarty DG, Masuki G et al. Age specific prevalence of impairment and disability relating to hemiplegic stroke in the Hai district of Northern Tanzania. Adult morbidity and mortality project. J Neurol Neurosurg Psychiatry 2000; 68: 744-9.
26. Camargo EC, Bacheschi LA, Massaro AR: Stroke in latin America. Neuroimaging Clin N Am 2005; 15: 283-96.
27. Jaillard AS, Hommel M, Mazetti P: Prevalence of stroke at high altitude (3380 m) in cuzco, a town of Peru. A population-based study. Stroke 1995; 26: 562-8.
28. Cabral NL, Longo AL, Moro CH, Amaral CH, Kiss HC: Epidemiology of cerebrovascular disease in joinville, Brazil. An institutional study. Arq Neuropsiquiatr 1997; 55: 357-63.
29. Del Brutto OH, Mosquera A, Sanchez X, Santos J, Noboa CA: Stroke subtypes among hispanics living in Guayaquil, Ecuador. Results from the Luis Vernaza Hospital stroke registry. Stroke 1993; 24: 1833-6.
30. Nicoletti A, Sofia V, Giuffrida S et al. Prevalence of stroke: door-to-door survey in rural Bolivia. Stroke 2000; 31: 882-5.
31. Lavados PM, Sacks C, Prina L et al. Incidence, 30-day case-fatality rate, and prognosis of stroke in Iquique, Chile: A 2-year community-based prospective study (PISCIS project). Lancet 2005; 365: 2206-15.
32. Del Brutto OH, Idrovo L, Mosquera A et al. Stroke in rural Ecuador: A three-phase, door-to-door survey. Neurology 2004; 63: 1974-5.
33. Lotufo PA: SAroke in Brazil: a neglected disease. Sao Paulo Med J 2005; 123: 3-4.
34. Feigin VL, Wiebers DO, Nikitin YP, O'Fallon WM, Whisnant JP: Stroke epidemiology in Novosibirsk, Russia: A population-based study. Mayo Clin Proc 1995; 70: 847-52.
35. Mihalka L, Smolanka V, Bulecza B, Mulesa S, Bereczki D: A population study of stroke in West Ukraine: Incidence, stroke services, and 30-day case fatality. Stroke 2001; 32: 2227-31.
36. Sarti C, Rastenyte D, Cepaitis Z, Tuomilehto J: International trends in mortality from stroke, 1968 to 1994. Stroke 2000; 31: 1588-601.
37. Rastenyte D, Tuomilehto J, Sarti C, Cepaitis Z, Bluzhas J: Trends in the incidence and mortality of stroke in Kaunas, Lithuania, 1986-1993. Cerebrovasc Dis 1996; 6: 13-20.
38. Wolf HK, Tuomilehto J, Kuulasmaa K et al. Blood pressure levels in the 41 populations of the WHO MONICA project. J Hum Hypertens 1997; 11: 733-42.
39. Murray CJ, Lopez AD (eds): The Global Burden of Disease, Vol 1. Boston: Harvard University press, 1996: 118-201.
40. Thammaroj J, Subramaniam V, Bhattacharya JJ: Stroke in Asia. Neuroimaging Clin N Am 2005; 15: 273-82.
41. Cheng XM, Ziegler DK, Lai YHC et al. Stroke in China, 1986 through 1990. Stroke 1995; 26: 1990-4.
42. Jiang B, Wang WZ, Chen H et al. Incidence and trends of stroke and its subtypes in China: Results from three large cities. Stroke 2006; 37: 63-8.
43. Suh DC, Lee SH, Kim KR et al. Pattern of atherosclerotic carotid stenosis in korean patients with stroke: Different involvement of intracranial versus extracranial vessels. An J Neuroradiol 2003; 24: 239-44.
44. Padma MV, Gaikwad S, Jain S, Maheswari MC, Misra NK: Distribution of vascular lesions in ischemic stroke: A magnetic resonance angiographic study. Natl Med J India 1997; 10: 217-20.
45. Dalal PM: Strokes in youRg and elderly: risk factors and strategies for stroke prevention. J Assoc Phys India 1997; 45: 125-31.
46. Saha SP, Bhattacharya S, Das SK, Maity B, Roy T, Raut DK: Epidemiological study of neurological disorders in a rural population of Eastern India. J Indian Med Assoc 2003; 101: 299-300, 302-4.
47. Dhamija RK, Dhamija SB: PrevalenceAof stroke in rural commuity: an overview of Indian experience. J Assoc Physicians India 1998; 46: 351-4.
48. Banerjee TK, Mukerjee CS, Sarkhel A: Stroke in the urban population of Calcutta-an epidemiological study. Neuroepidemiology 2001; 20: 201-7.
49. Razdan S, Koul RL, Motta A, Kaul S: Cereborvascular disease in rural Kashmir, India. Stroke 1989; 20: 1691-3.
50. Dalal PM: SIroke in India: issues in primary and secondary prevention. Neurol India 2002; 50: S2-7.
51. Anand K, Chowdhury D, Singh KB, Pandav CS, Kapoor SK: Estimation of mortality and morbidity due to stroke in India. Neuroepidemiology 2001; 20: 208-11.
52. Dalal PM: Strokes Pn the elderly: prevalence, risk factors and the strategies for prevention. Indian J Med Res 1997; 106: 325-32.
53. Ghandehari K, Moud ZI: Incidence and etiology of ischemic stroke in persian young adults. Acta Neurol Scand 2006; 113: 121-4.
54. Jafar TH: Blood pressure, diabetes, and increased dietary salt associated with stroke -results from a community-based study in Pakistan. J Hum Hypert 2006; 20: 83-5.
55. Massaro AR: Atroke in Brazil: a South America perspective. International Journal of Stroke 2006; 1: 113-5.
56. Sociedade Brasileira de Doencas Cerebrovasculares: (SBDCV). Brazilian consensus for the thrombolysis in acute ischemic stroke. Arq Neuropsiquiatr 2002; 60: 675-80.
57. Sposato L, Esnaola MM, Cirio JJ et al. Acute ischemic stroke treatment in Argentina. ReNACer: Argentinean Stroke Registry. Stroke 2006; 37: 657-8.
58. Brainin M, Bornstein N, Boysen G, Demarin V: Acute neurological care in Europe: Results of the european stroke care inventory. Eur J Neurol 2000; 7: 5-10.
59. Czlonkowska A, Sarzynska-Dlugosz I, Niewada M, Kobayashi A: Eligibility of stroke units in Poland for administration of intravenous thrombolysis. Eur J Neurol 2006; 13: 220-4.
60. May Z, Kakuk I, Ovary C et al. Thrombolysis in acute ischemic stroke with intravenous recombinant tissue-type plasminogen activator. Orv Hetil 2002; 143: 2479-84.
61. Gafurov BG, Zakhidov AIa: An experience of intra-arterial thrombolytic therapy of ischemic stroke in Uzbek republic center of emergency care. Zh Nevrol Psikhiatr Im S S Korsakova 2005: (Suppl. 15): 28-31.
62. Wei G, Ji X, Bai H, Ding Y: Stroke research in China. Neurol Res 2006; 28: 11-5.
63. Ko KF, Sheppard L: The contribution of a comprehensive stroke unit to the outcome of Chinese stroke patients. Singapore Med J 2006; 47: 208-12.
64. Chen OT: Intravenous thrombolysis with urokinase for acute cerebral infarctions. HKMJ 2001; 7: 7.
65. http://www.strokecenter.org/trials/Trialdetail.aspx. Accessed 20th June 2006.
66. Nandigam K, Narayan SK, Elangovan S, Dutta TK, Sethuraman KR, Das AK: Feasibility of acute thrombolytic therapy for stroke. Neurol India 2003; 51: 470-3.
67. Padma V, Soni D, Bhatia R, Srivastava A, Singh M: Thrombolysis in ischemic stroke: Experience from a tertiary care hospital in India. J Neurol Sci 2005; 238: S428.
68. Uppal A, Kapoor A: Experiences of thrombolytic therapy in acute ischemic stroke using NINDS criteria and imaging (NINDS plus) - an improved approach. Ann Indian Acad Neurol 2005; 8: 174.
69. Arjundas D, Sanjeev S, Sivakumar MR: Transcranial monitoring and sonothrombolysis in acute ischemic stroke. Ann Indian Acad Neurol 2005; 8: 210 (Abstract).
70. Prasad V, Kaul S, Meena A et al. Intravenous thrombolytic therapy in acute ischemic stroke in a university hospital of South India. J Neurol Sci 2005; 238 (Suppl. 1): S449 (Abstract).
71. Furlan A, Higashida R, Wechsler L et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: A randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999; 282: 2003-11.
72. Reed SD, Cramer SC, Blough DK, Meyer K, Jarvik JG: Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals. Stroke 2001; 32: 1832-40.
73. Sinclair SE, Frighetto L, Loewen PS et al. Cost-utility analysis of tissue plasminogen activator therapy for acute ischemic stroke. Pharmacoeconomics 2001; 19: 927-36.
74. Sandercock P, Berge E, Dennis M et al. Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs. Stroke 2004; 35: 1490-8.
75. Moodie ML, Carter R, Mihalopoulos C et al. Trial application of a model of resource utilization, costs, and outcomes for stroke (MORUCOS) to assist priority setting in stroke. Stroke 2004; 35: 1041-6.
76. Fagan S, Morgenstern L, Pettita A et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. Neurology 1998; 50: 883-90.
77. Chambers M, Koch P, Hutton J: Development of a decision-analytic model of stroke care in the United States and Europe. Value Health 2002; 5: 85-97.
78. Samsa GP, Reutter RA, Parmigiani G et al. Performing cost-effectiveness analysis by integrating randomized trial data with a comprehensive decision model: Application to treatment of acute ischemic stroke. J Clin Epidemiol 1999; 52: 259-71.
79. Demaerschalk BM, Yip TR: Economic benefit of increasing utilization of intravenous tissue plasminogen activator for acute ischemic stroke in the United States. Stroke 2005; 36: 2500-3.
80. Nilasena DS, Kreskowik TF, Wiblin RT et al. Assessing patterns of tPA use in acute stroke. Stroke 2002; 33: 354 (Abstract).
81. The World Bank, Entering the 21st century: World Development Report: 1999/2000. New York: Oxford University Press, 2000.
82. United Nations: Handbook of International Trade and Development Statistics, 1996-1997. New York: United Nations, 1999.
83. International Monitory Fund: Balance of Payments Statistics: Yearbook, Part 2: World and Regional Tables 1998. Washington, DC: International Monitory Fund, Publication Services, 1995.
84. Hu HH, Teng MM, Hsu LC et al. A pilot study of a new thrombolytic agent for acute ischemic stroke in taiwan within a five-hour window. Stroke 2006; 37: 918-9.
85. Srivastava AK, Prasad K: A study of factors delaying hospital arrival of patients with acute stroke. Neurology India 2001; 46: 272-6.
86. Yu RF, Cristina M, San Jose MC et al. Sources and reasons for delays in the care of acute stroke patients. J Neurol Sci 2002; 199: 49-54.
87. Misbach J, Ali A: Stroke in Indonesia: a first large prospective hospital-based study of acute stroke in 28 hospitals in Indonesia. J Clin Neurosci 2000; 8: 245-9.
88. Wang S, Niu S, Wang Y, Zhang G: Evaluation of the factors leading to delay from stroke onset to arrival at hospital. Zhonghua Nei Ke Za Zhi 2002; 41: 728-31.
89. Pandian JD, Kalra G, Jaison A et al. Factors delaying admission to a hospital-based stroke unit in India. J Stroke Cerebrovasc Dis 2006; 15: 81-7.
90. Pandian JD, Kalra G, Jaison A et al. Knowledge of stroke among stroke patients and their relatives in Northwest India. Neurol India 2006; 54: 152-6.
91. Cheung RT: Hong Kong patients' knowledge of stroke does not influence time-to-hospital presentation. J Clin Neurosci 2001; 8: 311-4.
92. Pandian JD, Jaison A, Deepak SS et al. Public awareness of warning symptoms, risk factors, and treatment of stroke in Northwest India. Stroke 2005; 36: 644-8.
93. Gong Z, Sucher NJ: Stroke therapy in traditional Chinese medicine (TCM): prospects for drug discovery and development. Phytomedicine 2002; 9: 478-84.
94. Caro JJ, Huybrechts KF, Duchesne I: Management pattern and costs of acute ischemic stroke: An international study for the stroke economic analysis group. Stroke 2000; 31: 582-90.
95. Tu F, Tokunaga S, Deng Z, Nobutomo K: Analysis of hospital charges for cerebral infarction stroke in patients in beijing, people's republic of China. Health Policy 2002; 59: 243-56.
96. Collaborative systematic review of the randomized trials of organized inpatients (stroke unit) care after stroke. stroke unit trialist's collaboration. BMJ 1997; 314: 1151-9.
97. The cinderella disease. Lancet Neurol 2005; 4: 263.
98. Yamaguchi T, Mori E, Minematsu K et al. Alteplase at 0.6mg/kg for acute ischemic stroke within 3 hours of onset. Japan aletplase clinical trial (J-ACT). Stroke 2006; 37: 1810-15.